Nama's AI scorecard currently rates Eton Pharmaceuticals Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ETON's P/E ratio?

Eton Pharmaceuticals trades at a trailing price-to-earnings ratio of 44.8.

When does ETON report earnings?

Eton Pharmaceuticals's next scheduled report is on Mar 25, 2027. Analysts expect EPS of $0.37.

What is the ETON price target?

The median analyst price target from 4 analysts is $70.00, with a range of $68.00 – $78.00.

Is ETON Shariah compliant?

Nama's AAOIFI-style screen reads Eton Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Eton Pharmaceuticals (ETON)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Eton Pharmaceuticals (ETON) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.61B, a trailing price-to-earnings ratio of 44.8 and a free-cash-flow yield of 0.7%. Over the most recent reported fiscal year, revenue grew 104.9%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +186.7% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-14.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.61B
Trailing P/E	44.8
Price / book	34.2
Price / sales	15.3
FCF yield	0.7%
Dividend yield	—
Gross margin	57.9%
Operating margin	15.4%
Net margin	12.0%
Revenue growth (YoY)	+104.9%
Revenue growth (3-yr annual)	+55.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

ETON earnings

Next report: Mar 25, 2027 (Q4 2026, EPS estimate $0.37). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.50	$0.37	+35.1%	—
Q2 2026	Aug 13, 2026	$0.43	$0.19	+126.3%	$37.59M
Q1 2026	May 14, 2026	$0.14	$0.14	+0.0%	$24.27M
Q4 2025	Mar 19, 2026	$0.19	$0.20	-5.0%	$21.28M

ETON analyst price target

Median target $70.00 from 4 analysts, ranging $68.00 – $78.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live ETON data on Nama Insights →

ETON FAQ

Is ETON a buy?: Nama's AI scorecard currently rates Eton Pharmaceuticals Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ETON's P/E ratio?: Eton Pharmaceuticals trades at a trailing price-to-earnings ratio of 44.8.
When does ETON report earnings?: Eton Pharmaceuticals's next scheduled report is on Mar 25, 2027. Analysts expect EPS of $0.37.
What is the ETON price target?: The median analyst price target from 4 analysts is $70.00, with a range of $68.00 – $78.00.
Is ETON Shariah compliant?: Nama's AAOIFI-style screen reads Eton Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.